LIST OF TABLES. Page No. No List of US Patents for FDDS Gastroretentive products available in the market

Size: px

Start display at page:

Download "LIST OF TABLES. Page No. No List of US Patents for FDDS Gastroretentive products available in the market"

Lionel Allison
5 years ago
Views:

1 LIST OF TABLES Sl. Table Title of the table List of US Patents for FDDS List of drugs explored for various floating dosage forms Gastroretentive products available in the market Standard plot data for Verapamil hydrochloride in ph Standard plot data for Rosiglitazone maleate in ph Standard plot data for Losartan potassium in ph Formulation chart of non-effervescent floating Losartan potassium tablets Formulation chart of effervescent floating Verapamil hydrochloride tablets Formulation chart of Rosiglitazone maleate hollow Relationship between angle of repose and powder flow Relationship between powder flowability & % compressibility Number of animals required for the in vivo evaluation studies Physical properties of non-effervescent floating tablets of Losartan potassium FT-IR spectral data of Losartan potassium and floating matrix tablet formulation G-VI DSC thermograms data of Losartan potassium & its floating matrix tablet formulation G- VI % Swelling data of non effervescent floating matrix tablet formulations in ph 1.2 HCl buffer In vitro release data of Losartan potassium from floating matrix tablet formulations Data of various parameters of model fitting for non effervescent floating matrix tablet formulations Stability study data of non effervescent floating tablet (G- VI) of Losartan potassium Physical properties of effervescent floating tablets of Verapamil hydrochloride 119 FT-IR Spectral data of effervescent floating tablet of Verapamil hydrochloride (B1) and Verapamil DSC thermogram data of effervescent floating tablet of Verapamil hydrochloride (B1) and Verapamil 123 V

2 Table Title of the table Effect of Sodium bicarbonate on onset and duration of floatation of effervescent floating tablet of Verapamil hydrochloride (B1) % Water uptake of effervescent floating tablets of Verapamil hydrochloride formulations in ph 1.2 In vitro drug release data of effervescent floating tablets of Verapamil hydrochloride in ph 1.2 Hydrochloric acid buffer(b1-b6) In vitro drug release data of effervescent floating tablets of Verapamil hydrochloride in ph 1.2 Hydrochloric acid buffer (B7-B13) Kinetic treatment of dissolution profile of tablets (Values of R 2, k, and n for tablets) and mechanism of drug release Stability study data of effervescent floating tablet formulation (B1) of Verapamil hydrochloride Percentage yield of Rosiglitazone maleate hollow Drug loading and encapsulation efficiency of prepared hollow of Rosiglitazone maleate FT-IR spectral data of Rosiglitazone maleate and hollow (F3) DSC thermograms data of Rosiglitazone maleate and hollow (F3) Sphericity values of Rosiglitazone maleate hollow Micromeritic properties of Rosiglitazone maleate hollow In vitro % floating ability data of hollow In vitro dissolution data of Rosiglitazone maleate hollow Data of various parameters of model fitting of dissolution profiles of hollow (values of R 2, k and n) and mechanism of drug release Stability study for drug content of Rosiglitazone maleate hollow (F3) VI

3 LIST OF FIGURES Sl.. Title of the Diagrammatic representation of internal view of 8 stomach Pictorial representation of the typical GI motility pattern 9 in fasting state Picturisation of various gastroretentive formulations 12 location in the stomach Schematic localization of an intragastric floating system 18 in the stomach Hydrodynamically balanced system (HBS) showing 19 gelatinous polymer barrier formation and drug release Improvement in HBS Swellable drug delivery systems Different geometric forms of unfoldable systems Different unfoldabe systems and Gastroretentive dosage 22 form before and after folding Schematic localization of a high density system in the 22 stomach SEM photographs of microballoon and microparticle Schematic presentation of the structure of low-density, 24 floating matrix tablets Intragastric floating drug delivery device Intragastric floating tablet Intragastric floating bilayer tablet Schematic representation of gas-generating systems as 29 monolayer drug delivery system Schematic illustration of the barrier formed by a raftforming system Diagrammatic sketch of the device representing its 31 operation mechanism(a,b,c,d) Gas generating systems Floating pills a) The penetration of water into effervescent layer leads to a CO 2 generation and makes the system to float (b) Mechanism of floatation UV-Spectra of Verapamil hydrochloride in ph Standard plot for Verapamil hydrochloride in ph UV-Spectra of Rosiglitazone maleate in ph Standard plot for Rosiglitazone maleate in ph UV-Spectra of Losartan potassium in ph VII

4 . Title of the Standard plot of Losartan potassium in ph Diagrammatic representation of preparation of hollow 79 by Quassi-emulsion technique Administration of alloxan by I.P route Administration of by oral gauze in 93 suspension form Blood collection from rat tail vein FT-IR spectra of Losartan potassium & its floating 101 matrix tablet formulation G-VI DSC thermograms of Losartan potassium & its floating 102 matrix tablet formulation G-VI Photographs of in vitro floating behavior and 103 dimensional changes of matrix tablet formulation Photographs showing swelling of floating matrix tablet 106 formulation in ph 1.2 HCl buffer Swelling profile of floating matrix tablet formulations in 107 ph 1.2 HCl buffer In vitro drug release profile of Losartan potassium from 110 floating matrix tablet formulations X-ray images showing gastric retention of floating matrix tablet formulation G-VI in a rabbit model at different time intervals % Drug content in the non effervescent floating tablet of Losartan potassium G-VI when stored at 25 ± 2 C & 60 ± 5 % RH for 12 months % Drug content in the non effervescent floating tablet of Losartan potassium G-VI when stored at 30 ± 2 o C/65 ± 5 % RH for 12 months % Drug content in the non effervescent floating tablet of Losartan potassium G-VI when stored at 40 ± 2 C & 75 ± 5 % RH for 6 months FT-IR Spectra of effervescent floating tablet of Verapamil Hydrochloride (B1) and Verapamil DSC thermograms of effervescent floating tablet of Verapamil hydrochloride (B1) and Verapamil Effect of amount Sodium bicarbonate on floating lag time of effervescent floating tablet of Verapamil hydrochloride (B1) Photographs of in vitro floating behavior of effervescent 126 floating tablet at different time intervals Effect of various concentrations of ingredients on swelling index of floating tablets of Verapamil hydrochloride at the end of 8 h VIII

5 Title of the Swelling behavior of effervescent floating tablet of Verapamil hydrochloride subjected to dissolution testing from 0-8h In vitro drug release profiles of Verapamil hydrochloride effervescent floating tablets (B1-B6) In vitro drug release profiles of Verapamil hydrochloride effervescent floating tablets (B7-B13) X-ray images showing gastric retention of effervescent floating tablet (B1) in a rabbit model at different time intervals % Drug content in the effervescent floating tablet of Verapamil hydrochloride (B-1) when stored at 25 ± 2 C & 60 ± 5 % RH for 12 months % Drug content in the effervescent floating tablet of Verapamil hydrochloride (B-1) when stored at 30 ± 2 o C/65 ± 5 % RH for 12 months % Drug content in the effervescent floating tablet of Verapamil hydrochloride (B-1) when stored at 40 ± 2 o C/75 ± 5 % RH for 06 months Prepared Rosiglitazone maleate hollow Bar graph of % encapsulation efficiency Bar graph of % drug loading FT-IR spectra of Rosiglitazone maleate and hollow 152 (F3) DSC thermograms of Rosiglitazone maleate pure drug 154 and hollow (F3) Scanning electron microscopic photograph of 155 at different magnifications Image using camera lucida showing sphericity of hollow 156 microsphere at 10x magnification Bar graph of particle size distribution of hollow Particle size distribution curve of F Bar graph of in vitro % floating hollow X-ray images showing floating ability of hollow 165 at different time intervals in rabbits In vitro drug release profile of Rosiglitazone maleate 169 hollow microsphere (F1-F6) In vitro drug release profile of Rosiglitazone maleate 169 hollow microsphere (F7-F11) Comparison of in vivo plasma glucose levels in alloxaninduced 173 diabetic albino rat following oral administration of pure drug (group III) and Rosiglitazone maleate hollow microsphere F3 (group IV), with plasma glucose levels of normal rat (group I) and alloxan-induced diabetic rat without drug (group II) IX

6 Title of the % Drug content in the hollow microsphere of Rosiglitazone maleate (F3) when stored at 25 ± 2 C & 60 ± 5 % RH for 12 months % Drug content in the hollow microsphere of Rosiglitazone maleate (F3) when stored at 30 ± 2 C & 65 ± 5 % RH for 12 months % Drug content in the hollow microsphere of Rosiglitazone maleate (F3) when stored at 40 ± 2 C & 75 ± 5 % RH for 12 months X

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

EVALUATION OF EFFERVESCENT FLOATING TABLETS 6.1 Technological characteristics of floating tablets 6.2 Fourier transform infrared spectroscopy (FT-IR) 6.3 Differential scanning calorimetry (DSC) 6.4 In